Zymeworks Inc. (ZYME): Total Assets
$346.53M
As of 2025-12-31
$396.96M
As of 2026-06-30
-18.9%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $346.53M | -25.2% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $463.09M | -20.3% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $580.88M | -10.5% | 2025-03-05, Balance as of period end |
| 2022-12-31 | $648.73M | +66.7% | 2024-03-06, Balance as of period end |
| 2021-12-31 | $389.13M | n/a | 2023-03-07, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Zymeworks Inc. (ZYME) | 2025-12-31 | $346.53M | -25.2% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $284.73M | +59.8% |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $485.57M | +37.1% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $200.46M | -29.8% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $166.13M | +32.5% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $219.47M | -10.2% |
| Xencor Inc (XNCR) | 2025-12-31 | $875.50M | -8.0% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $1.42B | +1.6% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $239.34M | -5.8% |
Compare ZYME, ZVRA, TBPH, URGN side by side · Screen every company in Pharmaceutical Preparations ↗